KSB licenses TransMID to Nycomed

KS Biomedix (LSE:KSB) granted Nycomed Group (Roskilde, Denmark) European rights to its TransMID therapeutic for brain cancer. TransMID has completed a U.S. Phase II trials to treat recurrent brain cancer. The companies will jointly fund development, and KSB will manufacture and sell TransMID materials to Nycomed, which will be responsible for registration and marketing of the product in Europe. KSB is eligible for upfront payments, milestones and royalties. ...